| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8889740 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Nov, 2025
(2 years from now) | |
| US8895616 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Nov, 2025
(2 years from now) | |
| US8796337 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Nov, 2025
(2 years from now) | |
| US8895617 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Nov, 2025
(2 years from now) | |
| US8895618 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Nov, 2025
(2 years from now) | |
| US8895614 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Nov, 2025
(2 years from now) | |
| US8895615 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Nov, 2025
(2 years from now) | |
| US8389578 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Jan, 2028
(4 years from now) | |
| US9877933 | ADAMAS PHARMA | Method of administering amantadine prior to a sleep period |
Dec, 2030
(7 years from now) | |
| US9867791 | ADAMAS PHARMA | Method of administering amantadine prior to a sleep period |
Dec, 2030
(7 years from now) | |
| US9867792 | ADAMAS PHARMA | Method of administering amantadine prior to a sleep period |
Dec, 2030
(7 years from now) | |
| US11197835 | ADAMAS PHARMA | Method of administering amantadine prior to a sleep period |
Dec, 2030
(7 years from now) | |
| US8741343 | ADAMAS PHARMA | Method of administering amantadine prior to a sleep period |
Dec, 2030
(7 years from now) | |
| US9867793 | ADAMAS PHARMA | Method of administering amantadine prior to a sleep period |
Dec, 2030
(7 years from now) | |
| US10646456 | ADAMAS PHARMA | Methods of administering amantadine |
Jun, 2034
(10 years from now) | |
| US10154971 | ADAMAS PHARMA | Methods of administering amantadine |
Dec, 2034
(11 years from now) | |
| US11065213 | ADAMAS PHARMA | Amantadine compositions and preparations thereof |
Aug, 2038
(14 years from now) | |
| US11077073 | ADAMAS PHARMA | Methods of using amantadine compositions |
Aug, 2038
(14 years from now) | |
Gocovri is owned by Adamas Pharma.
Gocovri contains Amantadine Hydrochloride.
Gocovri has a total of 18 drug patents out of which 0 drug patents have expired.
Gocovri was authorised for market use on 24 August, 2017.
Gocovri is available in capsule, extended release;oral dosage forms.
Gocovri can be used as treatment of dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, treatment of dyskinesia, decreasing off time, and increasing on time without troublesome dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, treatment of dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; treatment of dyskinesia and increasing on time without troublesome dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; decreasing off time in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, treatment of dyskinesia in patients with parkinson's disease receiving immediate release levodopa-based therapy, with or without concomitant dopaminergic medications, treatment of dyskinesia and increasing on time without troublesome dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, treatment of dyskinesia and decreasing off time in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
The generics of Gocovri are possible to be released after 23 August, 2038.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Aug 24, 2024 |
Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 24 August, 2017
Treatment: Treatment of dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; Treatment of dyskinesia in patients with parkinson'...
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
GOCOVRI family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic